Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 3, 2023
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
[ Mon, Apr 03rd 2023
] - WOPRAI
Sat, April 1, 2023
[ Sat, Apr 01st 2023
] - WOPRAI
Alec Stranahan Maintained (YMAB) at Hold and Held Target at $6 on, Apr 1st, 2023
Alec Stranahan of B of A Securities, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Hold and Held Target at $6 on, Apr 1st, 2023.
Alec has made no other calls on YMAB in the last 4 months.
There are 4 other peers that have a rating on YMAB. Out of the 4 peers that are also analyzing YMAB, 1 agrees with Alec's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Joseph Thome of "Cowen & Co." Downgraded from Buy to Hold on, Thursday, January 5th, 2023
These are the ratings of the 3 analyists that currently disagree with Alec
- William Maughan of "Canaccord Genuity" Maintained at Strong Buy with Decreased Target to $18 on, Friday, March 31st, 2023
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $13 on, Monday, January 30th, 2023
- Michael Ulz of "Morgan Stanley" Downgraded from Hold to Sell on, Friday, January 27th, 2023
